NCT00741377View on ClinicalTrials.gov

A Study to Assess BHQ880 in Combination With Zoledronic Acid in Relapsed or Refractory Myeloma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Multiple Myeloma Bone Disease
Interventions
DRUG

BHQ880

DRUG

Zoledronic acid

Trial Locations (9)

72703

Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville

78229

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4), San Antonio

85259

Mayo Clinic - Arizona Cancer Clinical Research Unit, Scottsdale

02115

Dana Farber Cancer Institute Deptof DanaFarberCancerInst(2), Boston

77030-4009

MD Anderson Cancer Center/University of Texas Dept. of MD Anderson (11), Houston

BD9 6RJ

Novartis Investigative Site, Bradford

EC1A 7BE

Novartis Investigative Site, London

SE1 9RT

Novartis Investigative Site, London

M20 4BX

Novartis Investigative Site, Manchester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY